← ANALYST RATINGS · TIPRANKS
Alvotech (ALVO): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy0 Hold0 Sell
Ratings of 3 analysts in the last 3 months12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $7.00, the highest $8.00, the lowest $6.00. The average is +40.0% from the last price of $5.00.
Analyst ratings 6
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI DeepSeek Drug Manufacturers - Specialty and GenericDeepSeek R1-0528 | TipRanks - DeepSeek | $5.00 → $5.50+10.0% | Hold | +10.0% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| AI Anthropic Drug Manufacturers - Specialty and GenericAnthropic Opus-4.1 | TipRanks - Anthropic | $5.00 → $5.50+10.0% | Hold | +10.0% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| AI Google Drug Manufacturers - Specialty and GenericGemini 2.5Pro | TipRanks - Google | $5.00 → $5.50+10.0% | Hold | +10.0% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| AI DeepSeek Drug Manufacturers - Specialty and GenericDeepSeek R1-0528 | TipRanks - DeepSeek | $5.50 → $5.00−9.1% | Hold | 0.0% | Reiterated | 15.10.26on TipRanks 17:05 | — | |
| AI Anthropic Drug Manufacturers - Specialty and GenericAnthropic Opus-4.1 | TipRanks - Anthropic | $5.50 → $5.00−9.1% | Hold | 0.0% | Reiterated | 15.10.26on TipRanks 17:05 | — | |
| AI Google Drug Manufacturers - Specialty and GenericGemini 2.5Pro | TipRanks - Google | $5.50 → $5.00−9.1% | Hold | 0.0% | Reiterated | 15.10.26on TipRanks 17:05 | — | |
| AI xAi Drug Manufacturers - Specialty and GenericxAI Grok-3 | TipRanks - xAI | $6.50 → $5.50−15.4% | Hold | +10.0% | Reiterated | 13.10.26on TipRanks 01:06 | — | |
| AI DeepSeek Drug Manufacturers - Specialty and GenericDeepSeek R1-0528 | TipRanks - DeepSeek | $6.00 → $5.50−8.3% | Hold | +10.0% | Reiterated | 13.10.26on TipRanks 01:06 | — | |
| AI OpenAI Drug Manufacturers - Specialty and GenericOpenAI 4o | TipRanks - OpenAI | $6.00 → $5.50−8.3% | Hold | +10.0% | Reiterated | 13.10.26on TipRanks 01:06 | — | |
| AI Anthropic Drug Manufacturers - Specialty and GenericAnthropic Opus-4.1 | TipRanks - Anthropic | $6.00 → $5.50−8.3% | Hold | +10.0% | Reiterated | 13.10.26on TipRanks 01:06 | — | |
| AI Google Drug Manufacturers - Specialty and GenericGemini 2.5Pro | TipRanks - Google | $6.00 → $5.50−8.3% | Hold | +10.0% | Reiterated | 13.10.26on TipRanks 01:06 | — | |
| AI PerPlexity Drug Manufacturers - Specialty and GenericPerPlexity SonarPro | TipRanks - PerPlexity | $6.50 → $5.50−15.4% | Hold | +10.0% | Reiterated | 13.10.26on TipRanks 01:06 | — | |
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | $7.00 | Buy | +40.0% | Assigned | 12.10.26on TipRanks 08:30 | −4.8%next day −2.2% | ↗ |
| AI xAi Drug Manufacturers - Specialty and GenericxAI Grok-3 | TipRanks - xAI | $6.00 → $6.50+8.3% | Hold | +30.0% | Reiterated | 06.10.26on TipRanks 11:05 | — | |
| AI DeepSeek Drug Manufacturers - Specialty and GenericDeepSeek R1-0528 | TipRanks - DeepSeek | $6.00 | Hold | +20.0% | Reiterated | 06.10.26on TipRanks 11:05 | — | |
| AI OpenAI Drug Manufacturers - Specialty and GenericOpenAI 4o | TipRanks - OpenAI | $6.00 | Hold | +20.0% | Reiterated | 06.10.26on TipRanks 11:05 | — | |
| AI Anthropic Drug Manufacturers - Specialty and GenericAnthropic Opus-4.1 | TipRanks - Anthropic | $6.00 | Hold | +20.0% | Reiterated | 06.10.26on TipRanks 11:05 | — | |
| AI Google Drug Manufacturers - Specialty and GenericGemini 2.5Pro | TipRanks - Google | $6.00 | Hold | +20.0% | Reiterated | 06.10.26on TipRanks 11:05 | — | |
| AI PerPlexity Drug Manufacturers - Specialty and GenericPerPlexity SonarPro | TipRanks - PerPlexity | $6.00 → $6.50+8.3% | Hold | +30.0% | Reiterated | 06.10.26on TipRanks 11:05 | — | |
| Glen Santangelo★★★★★★★★★★#2956 · hits 52% · avg +4.5% | Barclays | $8.00 | Buy | +60.0% | Upgrade | 16.09.26on TipRanks 03:50 | +2.0%next day +3.6% · 5 days +11.8% | ↗ |
| Ashwani Verma★★★★★★★★★★#1305 · hits 60% · avg +13.4% | UBS | $6.00 | Buy | +20.0% | Assigned | 24.08.26on TipRanks Aug 21 06:50 | +3.3%next day +18.8% · 5 days +11.3% | ↗ |
| Niall Alexander★★★★★★★★★★#7327 · hits 75% · avg +9.3% | Deutsche Bank | $8.00 → $4.00−50.0% | Hold | −20.0% | Reiterated | 24.03.26on TipRanks 08:55 | −5.7%next day −0.2% · 5 days +10.0% | ↗ |
| Thibault Boutherin★★★★★★★★★★#3632 · hits 62% · avg +7.0% | Morgan Stanley | $14.00 → $10.00−28.6% | Buy | +100.0% | Reiterated | 03.12.25on TipRanks 07:35 | +0.5%next day +9.2% · 5 days +18.6% | ↗ |
| Carl Byrnes★★★★★★★★★★#11765 · hits 37% · avg −4.0% | Northland Securities | $10.00 | Buy | +100.0% | Reiterated | 14.11.25on TipRanks 13:10 | −0.5%next day −5.4% · 5 days −4.5% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Alvotech
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 12.10.26: target $7.00 at a price of $5.78 (+21.1%); now: $7.00 at $5.00 (+40.0%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 0 | 0 | 0 | 1 | 1 |
| Buy | 0 | 0 | 0 | 2 | 2 | 3 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 1 | 1 | 2 | 2 | 1 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.02 (from $-0.07 to $0.02). Last quarter: $-0.09.
Sales
Next quarter’s sales estimate — $139M (from $94M to $167M). Last quarter: $106M.
Best top-analyst consensus in the sector · Healthcare
About Alvotech
- CEO: Lisa Graver
- Employees: 1,279
- 9, Rue de Bitbourg, Luxembourg, LU, 1273, LU
- www.alvotech.com
Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of inflammatory illnesses, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Similarly, AVT04 is a biosimilar version of Stelara, targeting inflammatory conditions such as psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. For ophthalmic conditions, AVT06 serves as a biosimilar to Eylea, intended for the treatment of age-related macular degeneration, macular edema, and diabetic retinopathy. Currently in preclinical stages, AVT03 is a biosimilar to Xgeva and Prolia, with the goal of preventing bone fractures, alleviating spinal cord compression, reducing the necessity for radiation or bone surgery in certain cancer patients, and both preventing bone loss and increasing bone density. Additionally, Alvotech's pipeline features AVT05, an early-stage biosimilar for Simponi and Simponi Aria, which is being developed for various inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Other promising candidates include AVT16, an immunology biosimilar; AVT23, a late-stage biosimilar to Xolair, aimed at treating nasal polyps; and AVT33, an oncology biosimilar. Established in 2013, Alvotech maintains its primary corporate headquarters in Reykjavik, Iceland.
Data from the stock’s TipRanks forecast page, read 150 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗